330 related articles for article (PubMed ID: 3806749)
1. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases.
Costa JM; Marsden PD; Llanos-Cuentas EA; Netto EM; Carvalho EM; Barral A; Rosa AC; Cuba CC; Magalhães AV; Barreto AC
J Trop Med Hyg; 1986 Dec; 89(6):319-23. PubMed ID: 3806749
[TBL] [Abstract][Full Text] [Related]
2. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.
Romero GA; de la Glória Orge Orge M; de Farias Guerra MV; Paes MG; de Oliveira Macêdo V; de Carvalho EM
Acta Trop; 2005 Jan; 93(1):49-56. PubMed ID: 15589797
[TBL] [Abstract][Full Text] [Related]
3. Apparent Glucantime failure in five patients with mucocutaneous leishmaniasis.
Rocha RA; Sampaio RN; Guerra M; Magalhâes A; Cuba CC; Barreto AC; Marsden PD
J Trop Med Hyg; 1980 Aug; 83(4):131-9. PubMed ID: 6997505
[TBL] [Abstract][Full Text] [Related]
4. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
Rezzano S; Armas JA; Moreno G; Scorza JV
Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
[No Abstract] [Full Text] [Related]
5. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
6. Development of Leishmania (Viannia) panamensis lesions and relationship of numbers of amastigotes to lesion area on antimony-treated and untreated hamsters.
Hanson WL; Chapman WL; Waits VB; Lovelace JK
J Parasitol; 1991 Oct; 77(5):780-3. PubMed ID: 1919929
[TBL] [Abstract][Full Text] [Related]
7. Intralesional glucantime in Leishmania braziliensis braziliensis infections.
Barrios LA; Costa JM; Netto EM; Vexenat CO; Cuba CC; Marsden PD
Trans R Soc Trop Med Hyg; 1986; 80(1):173-4. PubMed ID: 3726989
[No Abstract] [Full Text] [Related]
8. Leishmaniasis.
Evans TG
Infect Dis Clin North Am; 1993 Sep; 7(3):527-46. PubMed ID: 8254158
[TBL] [Abstract][Full Text] [Related]
9. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.
Botelho AC; Mayrink W; Oliveira RC
Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187
[TBL] [Abstract][Full Text] [Related]
10. Human american cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy.
Mendonça SC; Coutinho SG; Amendoeira RR; Marzochi MC; Pirmez C
Clin Exp Immunol; 1986 May; 64(2):269-76. PubMed ID: 3742876
[TBL] [Abstract][Full Text] [Related]
11. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil.
Mayrink W; Magalhaes PA; Michalick MS; da Costa CA; Lima Ade O; Melo MN; Toledo VP; Nascimento E; Dias M; Genaro O
Parassitologia; 1992 Dec; 34(1-3):159-65. PubMed ID: 1339971
[TBL] [Abstract][Full Text] [Related]
13. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime.
Netto EM; Marsden PD; Llanos-Cuentas EA; Costa JM; Cuba CC; Barreto AC; Badaró R; Johnson WD; Jones TC
Trans R Soc Trop Med Hyg; 1990; 84(3):367-70. PubMed ID: 2260171
[TBL] [Abstract][Full Text] [Related]
15. American cutaneous leishmaniasis: disappearance of amastigotes from lesions during antimonial therapy.
Mayrink W; Raso P; Melo MN; Michalick MS; Magalhães PA; Williams P; da Costa CA; Dias M
Rev Inst Med Trop Sao Paulo; 1983; 25(6):265-9. PubMed ID: 6672988
[No Abstract] [Full Text] [Related]
16. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections.
Silveira FT; Lainson R; Shaw JJ; De Souza AA; Ishikawa EA; Braga RR
Trans R Soc Trop Med Hyg; 1991; 85(6):735-8. PubMed ID: 1801340
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous leishmaniasis].
Vion B
Rev Med Suisse Romande; 1989 Jun; 109(6):443-9. PubMed ID: 2547241
[No Abstract] [Full Text] [Related]
19. Diffuse cutaneous leishmaniasis acquired in Peru.
Franke ED; Lucas CM; Tovar AA; Kruger JH; De Rivera MV; Wignall FS
Am J Trop Med Hyg; 1990 Sep; 43(3):260-2. PubMed ID: 2221221
[TBL] [Abstract][Full Text] [Related]
20. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil.
Amato VS; Tuon FF; Imamura R; Abegão de Camargo R; Duarte MI; Neto VA
J Eur Acad Dermatol Venereol; 2009 Sep; 23(9):1026-34. PubMed ID: 19453817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
